Published in J Thromb Haemost on July 17, 2006
Platelets as immune mediators: their role in host defense responses and sepsis. Thromb Res (2010) 1.04
Platelets in inflammation and atherogenesis. Front Immunol (2015) 0.94
Inhibition of vascular ectonucleotidase activities by the pro-drugs ticlopidine and clopidogrel favours platelet aggregation. Br J Pharmacol (2010) 0.92
Novel uses for anti-platelet agents as anti-inflammatory drugs. Br J Pharmacol (2007) 0.90
Lack of evidence for pleiotropic effects of clopidogrel on endothelial function and inflammation in patients with stable coronary artery disease: results of the double-blind, randomized CASSANDRA study. Clin Res Cardiol (2010) 0.82
Cerebral infarction in idiopathic thrombocytopenic purpura: a case report. BMJ Case Rep (2009) 0.78
8-BuS-ATP derivatives as specific NTPDase1 inhibitors. Br J Pharmacol (2013) 0.77
Unveiling the inflammatory face of antiplatelet drugs. J Thromb Haemost (2006) 0.75
Influence of genetic variations on levels of inflammatory markers of healthy subjects at baseline and one week after clopidogrel therapy; results of a preliminary study. Int J Mol Sci (2013) 0.75
No effect of clopidogrel activity or cessation on vascular function or markers of inflammation. Int J Angiol (2012) 0.75
Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med (1994) 3.73
[Bleeding complications of spinal and epidural analgesia]. Tidsskr Nor Laegeforen (1998) 2.66
Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet (1995) 2.43
One year's treatment with propranolol after myocardial infarction: preliminary report of Norwegian multicentre trial. Br Med J (Clin Res Ed) (1982) 2.39
High-intensity interval training improves peak oxygen uptake and muscular exercise capacity in heart transplant recipients. Am J Transplant (2012) 2.08
Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol (1985) 2.06
Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection--correlations to clinical, immunologic, and virologic parameters. J Infect Dis (1994) 1.93
Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol (1999) 1.86
Elevated levels of serum-soluble CD14 in human immunodeficiency virus type 1 (HIV-1) infection: correlation to disease progression and clinical events. Blood (1998) 1.83
CXC-chemokines, a new group of cytokines in congestive heart failure--possible role of platelets and monocytes. Cardiovasc Res (2000) 1.74
Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess--possible role in bone homeostasis. Eur J Endocrinol (2001) 1.71
Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort Study. Eur Respir J (2009) 1.62
Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab (1999) 1.61
Disease and acetylation polymorphism. Clin Pharmacokinet (1977) 1.56
Myocardial gene expression of leukaemia inhibitory factor, interleukin-6 and glycoprotein 130 in end-stage human heart failure. Eur J Clin Invest (2001) 1.55
IL-10 in HIV infection: increasing serum IL-10 levels with disease progression--down-regulatory effect of potent anti-retroviral therapy. Clin Exp Immunol (1999) 1.55
Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure. Cardiovasc Res (2000) 1.53
Osteoprotegerin concentrations and prognosis in acute ischaemic stroke. J Intern Med (2009) 1.53
Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation (1999) 1.53
Omega-3 fatty acids improve blood pressure control and preserve renal function in hypertensive heart transplant recipients. Eur Heart J (2001) 1.51
Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol (1999) 1.50
Primary immunodeficiency diseases in Norway. J Clin Immunol (2000) 1.48
Elevated plasma levels of reduced homocysteine in common variable immunodeficiency--a marker of enhanced oxidative stress. Eur J Clin Invest (1997) 1.48
Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis. Arterioscler Thromb Vasc Biol (1997) 1.46
Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial. Am J Transplant (2014) 1.46
Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation (1998) 1.46
Virtual histology assessment of cardiac allograft vasculopathy following introduction of everolimus--results of a multicenter trial. Am J Transplant (2012) 1.45
Immunochemical evidence for protein abnormalities in platelets from patients with Glanzmann's thrombasthenia and Bernard-Soulier syndrome. J Clin Invest (1980) 1.45
When should heparin preferably be administered during radiofrequency catheter ablation? Pacing Clin Electrophysiol (2001) 1.43
Biochemical markers of bone metabolism in benign human osteopetrosis: a study of two types at baseline and during stimulation with triiodothyronine. Eur J Endocrinol (1998) 1.42
[Immunomodulating treatment in advanced heart failure--effect of intravenous immunoglobulin]. Tidsskr Nor Laegeforen (2001) 1.40
[Natural products can be hazardous to health]. Tidsskr Nor Laegeforen (1992) 1.39
[The chemical working environment among car painters in Bergen]. Tidsskr Nor Laegeforen (1994) 1.39
Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type 1 infection. FASEB J (1998) 1.35
Congenital thrombocytopenia with giant platelets: a defect in the platelet membrane. Br J Haematol (1969) 1.34
Subnormal serum concentration of 1,25-vitamin D in human immunodeficiency virus infection: correlation with degree of immune deficiency and survival. J Infect Dis (1994) 1.33
Interferons and interferon (IFN)-inducible protein 10 during highly active anti-retroviral therapy (HAART)-possible immunosuppressive role of IFN-alpha in HIV infection. Clin Exp Immunol (2000) 1.32
Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation (2001) 1.29
Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. J Clin Endocrinol Metab (1998) 1.29
Cardiopulmonary exercise testing and prognosis in severe heart failure: 14 mL/kg/min revisited. Am Heart J (2000) 1.28
Clinical, hemodynamic, and cardiopulmonary exercise test determinants of survival in patients referred for evaluation of heart failure. Ann Intern Med (1998) 1.26
Interaction between chemokines and oxidative stress: possible pathogenic role in acute coronary syndromes. J Am Coll Cardiol (2001) 1.18
Platelet glycocalicin. Its membrane association and solubilization in aqueous media. Biochim Biophys Acta (1980) 1.18
Some characteristics of the clottable protein of limulus polyphemus blood cells. Thromb Diath Haemorrh (1970) 1.13
Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood (1994) 1.12
LRP5 gene polymorphisms predict bone mass and incident fractures in elderly Australian women. Bone (2005) 1.11